Inflammaging, metabolic syndrome and melatonin : a call for treatment studies

Abstract: The metabolic syndrome (MS) is a collection of risk factors for cardiovascular disease, including obesity, hypertension, hyperinsulinemia, glucose intolerance and dyslipidemia. MS is associated with low-grade inflammation of the white adipose tissue, which can subsequently lead to insulin...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cardinali, Daniel Pedro, Hardeland, Rüdiger
Formato:	Artículo
Lenguaje:	Inglés Inglés
Publicado:	Karger Publishers 2019
Materias:	MEDICINA MELATONINA SINDROME METABOLICO BIOMEDICINA ESCLEROSIS MULTIPLE ENVEJECIMIENTO INFLAMACION OBESIDAD DIABETES INSULINA
Acceso en línea:	https://repositorio.uca.edu.ar/handle/123456789/1450
Aporte de:	Repositorio Institucional de la Universidad Católica Argentina (UCA) de Universidad Católica Argentina

Ejemplares similares

Cytoprotection by melatonin: The metabolic syndrome as an example
por: Cardinali, Daniel Pedro, et al.
Publicado: (2022)

Melatonin, mitochondria, and the metabolic syndrome
por: Cardinali, Daniel Pedro, et al.
Publicado: (2019)

Melatonin and brain inflammaging
por: Hardeland, Rüdiger, et al.
Publicado: (2019)

The polycystic ovary syndrome and the metabolic syndrome : a possible chronobiotic-cytoprotective adjuvant therapy
por: Spinedi, Eduardo J., et al.
Publicado: (2019)

Melatonin and the metabolic syndrome : physiopathologic and therapeutical implications
por: Cardinali, Daniel Pedro, et al.
Publicado: (2019)

Melatonin may curtail the metabolic syndrome : studies on initial and fully established fructose-induced metabolic syndrome in rats
por: Cardinali, Daniel Pedro, et al.
Publicado: (2019)

Can melatonin be a potential “silver bullet” in treating covid-19 patients?
por: Cardinali, Daniel Pedro, et al.
Publicado: (2022)

Melatonin as a chronobiotic/cytoprotector : its role in healthy aging
por: Cardinali, Daniel Pedro
Publicado: (2020)

Metabolic syndrome prevalence and clinical features in blood donors
por: Cruz del Castillo, Aaron H., et al.
Publicado: (2012)

Are melatonin doses employed clinically adequate for melatonin-induced cytoprotection?
por: Cardinali, Daniel Pedro
Publicado: (2019)

Melatonin and diet-induced metabolic syndrome in rats. Impact on the hypophysial-testicular axis
por: Scacchi Bernasconi, Pablo A., et al.
Publicado: (2019)

Melatonin : a pleiotropic, orchestrating regulator molecule
por: Srinivasan, Venkataramanujan, et al.
Publicado: (2019)

METABOLIC SYNDROME AND OBESITY ACCORDING TO IFD/LAAD CRITERIA IN ADULTS IN THE CITY OF SALTA
por: Gotthelf, Susana Judith, et al.
Publicado: (2018)

Rol antiinflamatorio y restaurador de la melatonina en el síndrome metabólico asociado a enfermedad periodontal en ratas
por: Vázquez Mosquera, Ana Paula
Publicado: (2024)

The Metabolic syndrome and metabolic characteristics in blood donors
por: Aro, Pedro, et al.
Publicado: (2024)

Neuroendocrine-metabolic dysfunction and sleep disturbances in neurodegenerative disorders: focus on Alzheimer's disease and melatonin
por: Spinedi, Eduardo J., et al.
Publicado: (2019)

Melatonin and healthy aging
por: Cardinali, Daniel Pedro
Publicado: (2023)

Disrupted chronobiology of sleep and cytoprotection in obesity : possible therapeutic value of melatonin
por: Cardinali, Daniel Pedro, et al.
Publicado: (2019)

Detección de síndrome metabólico en pacientes obesos y su vinculación con resistencia a la insulina, patologías cardiovasculares y diabetes
por: Capurro, Agustín Manuel
Publicado: (2009)

Comparison of glycemic control in diabetic patients with and without metabolic syndrome
por: Cruz del Castillo, Aaron Humberto, et al.
Publicado: (2013)

Systematic review and meta-analysis on the relationship between prenatal stress and metabolic syndrome intermediate phenotypes
por: Burgueño, Adriana, et al.
Publicado: (2020)

Systematic review and meta-analysis on the relationship between prenatal stress and metabolic syndrome intermediate phenotypes
por: Burgueño, Adriana Laura, et al.
Publicado: (2020)

Pharmacological analysis of metabolic syndrome appraised by oxidative stress markers
por: Castillo, TA, et al.
Publicado: (2019)

Metabolic alterations observed in patients undergoing endocrinological follow-up during the first year of confinement due to Covid-19
por: Tibaldo, María Cecilia, et al.
Publicado: (2024)

Neuroprotection from protein misfolding in cerebral hypoperfusion concurrent with metabolic syndrome: a translational perspective
por: Bordet, Sofía, et al.
Publicado: (2023)

Neuroprotection in metabolic syndrome by environmental enrichment: a lifespan perspective
por: Kobiec, Tamara, et al.
Publicado: (2023)

Melatonin-induced oncostasis, mechanisms and clinical relevance
por: Cardinali, Daniel Pedro, et al.
Publicado: (2019)

Coadministration of melatonin and insulin improves diabetes-induced impairment of rat kidney function
por: Hajam, Younis Ahmad, et al.
Publicado: (2022)

Obesidad, hipertensión, síndrome metabólico y diabetes mellitus tipo 2 en dadores de sangre, individuos presuntamente sanos, del banco de sangre, tejidos y biológicos, de la ciudad de Posadas
por: Blariza, Gabriela M., et al.
Publicado: (2019)

Assessing the efficacy of melatonin to curtail benzodiazepine/Z drugabuse
por: Cardinali, Daniel Pedro, et al.
Publicado: (2019)

Efectos del glutamato monosódico sobre parámetros del síndrome metabólico en ratas obesas y diabéticas
por: Revelant, Gilda, et al.
Publicado: (2020)

Efectos del glutamato monosódico sobre parámetros del síndrome metabólico en ratas obesas y diabéticas
por: Revelant, Gilda, et al.
Publicado: (2020)

Commentary on the article published by Russel Reiter and Daniel Cardinali and their collaborators: Melatonin: highlighting its use as a potential treatment for SARS-CoV-2 infection
por: Pasqualini, María Eugenia
Publicado: (2022)

Falls risk, circadian rhythms and melatonin : current perspectives
por: Goswami, Nandu, et al.
Publicado: (2021)

Falls risk, circadian rhythms and melatonin : current perspectives
por: Goswami, Nandu, et al.
Publicado: (2021)

Neuroprotection targeting protein misfolding on chronic cerebral hypoperfusion in the context of metabolic syndrome
por: Herrera, María I., et al.
Publicado: (2019)

Neuroprotection targeting protein misfolding on chronic cerebral hypoperfusion in the context of metabolic syndrome
por: Herrera, María Inés, et al.
Publicado: (2019)

Melatonina y consumo de benzodiacepinas : un ejemplo de medicina traslacional
por: Cardinali, Daniel Pedro, et al.
Publicado: (2019)

Melatonin effect on plasma adiponectin, leptin, insulin, glucose, triglycerides and cholesterol in normal and high-fat fed rats
por: Ríos Lugo, María J., et al.
Publicado: (2019)

Resistencia a la insulina e hipertensión arterial.
por: Lima, Nereida